氯雷他定联合地氯雷他定治疗儿童慢性自发性荨麻疹的临床观察  

Loratadine in combination with desloratadine for the treatment of chronic spontaneous urticaria in children： a clinical observation

作　　者：周顺龙[1] 许恩超[1] 邓雯[1] 卢宏昌[1] 李荣珍[1] 黄敏[1] 

机构地区：[1]江西省儿童医院皮肤科,南昌330006

出　　处：《中华皮肤科杂志》2017年第1期46-48,共3页Chinese Journal of Dermatology

摘　　要：目的探讨氯雷他定联合地氯雷他定治疗儿童慢性自发性荨麻疹的临床疗效及安全性。方法177例儿童自发性慢性荨麻疹患儿分为3组。根据年龄，试验组每日晨服地氯雷他定，同时每晚睡前口服氯雷他定，连用28d。对照1组每日晨服安慰剂（淀粉压片）半片，每晚睡前口服氯雷他定，连用28d。对照2组每日晨服安慰剂半片，同时每晚睡前口服地氯雷他定，连用28d。于用药后随访观察药物的可能不良反应及疗程结束时药物的疗效。结果试验组、对照1组及对照2组有效率分别为90．9％、71．4％和74．5％，试验组有效率优于对照组（，值分别为6．865、5．153，均P〈0．05），3个组不良反应发生率分别为10．9％、8．9％、9．1％，3个组不良反应发生率比较，差异无统计学意义（P〉0．05）。结论氯雷他定联合地氯雷他定治疗儿童慢性自发性荨麻疹优于单用氯雷他定或单用地氯雷他定治疗，3个组不良反应发生率差异无统计学意义。Objective To evaluate clinical efficacy and safety of loratadine combined with desloratadine in the treatment of chronic spontaneous urticaria （CSU） in children. Methods A total of 177 children with CSU were enrolled into this study, and randomly and equally divided into 3 groups： combination group treated with an age-based dose of desloratadine tablet every morning and a weight-based dose of loratadine tablet before sleep every night for consecutive 28 days, loratadine group treated with a half tablet of placebo （starch tablet） every morning and oral loratadine tablet before sleep every night for consecutive 28 days, and desloratadine group treated with a half tablet of placebo （starch tablet） every morning and oral desloratadine tablet before sleep every night for 28 consecutive days. Possible adverse reactions were observed and recorded after the start of treatment, and therapeutic effects were evaluated at the end of treatment. Results A total of 166 patients completed the trial, including 55 in the combination group, 56 in the loratadine group and 55 in the desloratadine group. After 28-day treatment, the total response rate was significantly higher in the combination group （90.9%, 50/55） than in the loratadine group （71.4%[40/561, x^2 = 6.865, P 〈 0.05） and desloratadine group （74.5%[41/55], x^2 = 5.153, P 〈 0.05）. No significant difference in the incidence of adverse reactions was observed among the combination group （10.9% [6/55] ）, loratadine group （8.9% [5/56] ） and desloratadine group （9.1% [5/55], P 〉 0.05）. Conclusion Combination of loratadine and desloratadine was superior to loratadine or desloratadine alone in the treatment of childhood CSU, and there was no significant difference in the incidence of adverse reactions among the 3 treatment groups.

关 键 词：荨麻疹 氯雷他定 随机对照试验 儿童 地氯雷他定 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]